Paper41799211
In vivo Expansion of Regulatory T cells via an Engineered IL-2 Mutein to Suppress Autoimmune Glomerulonephritis.
Kuang H and 11 others. Theranostics, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. In vivo Expansion of Regulatory T cells via an Engineered IL-2 Mutein to Suppress Autoimmune Glomerulonephritis. Papers, record 41799211. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41799211
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- In vivo Expansion of Regulatory T cells via an Engineered IL-2 Mutein to Suppress Autoimmune Glomerulonephritis.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| T-Lymphocytes, Regulatory | Major topic |
| Interleukin-2 | Major topic |
| Glomerulonephritis | Major topic |
| Autoimmune Diseases | Major topic |
| Animals | |
| Humans | |
| Macaca fascicularis | |
| Mice | |
| Disease Models, Animal | |
| Female | |
| Recombinant Fusion Proteins | |
| Lymphocyte Activation |
Source PubMed
References46
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34306974 | In Vivo Induction of Regulatory T Cells Via CTLA-4 Signaling Peptide to Control Autoimmune Encephalomyelitis and Prevent Disease Relapse. | Adv Sci (Weinh) | 2021 | https://conductscience.org/library/papers/34306974 | PubMed |
| 2 | 18510923 | Regulatory T cells and immune tolerance. | Cell | 2008 | https://conductscience.org/library/papers/18510923 | PubMed |
| 3 | 37598856 | Autoantibodies against laminin-521 are pathogenic in anti-glomerular basement membrane disease. | Kidney Int | 2023 | https://conductscience.org/library/papers/37598856 | PubMed |
| 4 | 34593809 | Membranous nephropathy. | Nat Rev Dis Primers | 2021 | https://conductscience.org/library/papers/34593809 | PubMed |
| 5 | 32843568 | Persistent IL-2 Receptor Signaling by IL-2/CD25 Fusion Protein Controls Diabetes in NOD Mice by Multiple Mechanisms. | Diabetes | 2020 | https://conductscience.org/library/papers/32843568 | PubMed |
| 6 | 11986199 | The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. | Blood | 2002 | https://conductscience.org/library/papers/11986199 | PubMed |
| 7 | 15638990 | Stability of Ala 125 recombinant human interleukin-2 in solution. | J Pharm Pharmacol | 2005 | https://conductscience.org/library/papers/15638990 | PubMed |
| 8 | 33571932 | Altered Th17/Treg ratio as a possible mechanism in pathogenesis of idiopathic membranous nephropathy. | Cytokine | 2021 | https://conductscience.org/library/papers/33571932 | PubMed |
| 9 | 27578889 | Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. | Protein Eng Des Sel | 2016 | https://conductscience.org/library/papers/27578889 | PubMed |
| 10 | 33993908 | Changes and significance of Treg and Th17 in adult patients with primary membranous nephropathy. | Clin Nephrol | 2021 | https://conductscience.org/library/papers/33993908 | PubMed |
| 11 | 23446139 | CD4+Foxp3+ regulatory T cells prolong drug-induced disease remission in (NZBxNZW) F1 lupus mice. | Arthritis Res Ther | 2013 | https://conductscience.org/library/papers/23446139 | PubMed |
| 12 | 39232245 | The pathogenesis of IgA nephropathy and implications for treatment. | Nat Rev Nephrol | 2025 | https://conductscience.org/library/papers/39232245 | PubMed |
| 13 | 35484394 | Membranous nephropathy: new pathogenic mechanisms and their clinical implications. | Nat Rev Nephrol | 2022 | https://conductscience.org/library/papers/35484394 | PubMed |
| 14 | 12391178 | Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. | J Immunol | 2002 | https://conductscience.org/library/papers/12391178 | PubMed |
| 15 | 31811270 | Treg cell-based therapies: challenges and perspectives. | Nat Rev Immunol | 2020 | https://conductscience.org/library/papers/31811270 | PubMed |
| 16 | 12925844 | CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. | Nat Med | 2003 | https://conductscience.org/library/papers/12925844 | PubMed |
| 17 | 37741949 | "IL-2 immunotherapy for targeting regulatory T cells in autoimmunity". | Genes Immun | 2023 | https://conductscience.org/library/papers/37741949 | PubMed |
| 18 | 15184499 | In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. | J Exp Med | 2004 | https://conductscience.org/library/papers/15184499 | PubMed |
| 19 | 36334986 | Autoimmunity in Anti-Glomerular Basement Membrane Disease: A Review of Mechanisms and Prospects for Immunotherapy. | Am J Kidney Dis | 2023 | https://conductscience.org/library/papers/36334986 | PubMed |
| 20 | 15184500 | CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. | J Exp Med | 2004 | https://conductscience.org/library/papers/15184500 | PubMed |
Genes29
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41799211
GET https://conductscience.org/api/papers/v1/41799211/references?page=2